Featured Research

from universities, journals, and other organizations

Anti-TNF therapy fails to relieve pain caused by hand osteoarthritis, study suggests

Date:
November 11, 2012
Source:
American College of Rheumatology (ACR)
Summary:
A new study suggests that anti-tumor necrosis factor drugs (also called anti-TNF) offer no relief to patients with chronic pain caused from hand osteoarthritis.

A new study presented this week at the American College of Rheumatology Annual Meeting in Washington D.C., suggests that anti-tumor necrosis factor drugs (also called anti-TNF) offer no relief to patients with chronic pain caused from hand osteoarthritis.

Osteoarthritis, or OA as it is commonly called, is the most common joint disease affecting middle-age and older people. It is characterized by progressive damage to the joint cartilage -- the cushioning material at the end of long bones. It can causes changes in the structures around the joint including fluid accumulation, bony overgrowth, and weakness of muscles and tendons, all of which may limit movement and cause pain and swelling.

People with hand osteoarthritis often experience pain in multiple joints and previous studies have documented that the disease does not respond to several of the traditional therapies used in its treatment. However, anti-TNF medications may represent a real hope, because TNF is a molecule found to contribute to the destruction of cartilage and inflammation of joints. Researchers on behalf of the French National Section on OA (led by the Hopital Henri Mondor ) in France recently compared the effectiveness of TNF blockers (commonly called anti-TNFs) and nonsteroidal anti-inflammatory drugs (also called NSAIDs) in controlling pain in people with hand OA.

The digital osteoarthritis in refractory hand OA study (called DORA) included hand OA patients who did not respond to painkillers and NSAIDs. Patients also had to meet the American College of Rheumatology criteria for hand OA with significant pain, at least three painful inter phalangeal hand joints and a minimum of three involved joints identified by X-ray. The study was conducted at 16 different clinical sites. Eighty-five patients were randomly divided into two groups. One group received adalimumab (Humiraฎ), and the other group received placebo. Neither the patients nor the researchers were told who was in which group. Patients were monitored for 26 weeks. Those in the adalimumab group received two injections of the therapy at the beginning and second week of the trial.

Researchers established that a change of more than 50 percent in improvement in pain score after six weeks would be considered therapeutic success. Additional signs of success after six weeks included fewer painful and swollen joints, decreased morning stiffness and improved patient and practitioner assessments. Researchers monitored use of painkillers (acetaminophen up to three grams daily was the only medication allowed until week six) and the progression of the disease using blood and urine tests.

Of the 85 patients (42 in the placebo group, 41 in the adalimumab group), 35 in the placebo group and 38 in the adalimumab group received the two injections. Seventy-eight patients with at least one injection were analyzed (37 placebo and 41 adalimumab). The mean age of the patients was 62.5 years; 85 percent were women. Mean pain level at study beginning was 65.4 millimeters on a zero to 100 mm scale; and patients had a mean of 11 painful joints, and 5.9 clinically inflamed digital joints.

After six weeks of receiving adalimumab and placebo, researchers measured only a 2.5 millimeter difference in the average change in pain score between the groups. At week six, there was no difference between groups on the main outcome -- where they measured 50 percent improvement (35.1 percent in the adalimumab group versus 27.3 percent in the placebo group). The only difference recorded was a decrease in the number of swollen joints between week zero and week 26 in the adalimumab group. No other significant changes or concerns were reported.

"Our research found that two injections of anti-TNF failed to improve severe painful hand OA," says Xavier Chevalier, MD, PhD, head of the department of rheumatology at Hopital Henri Mondor in France and lead investigator of the study. "New trials are needed to find the right target in painful hand OA because this is a disease where we have no real therapy and the patients develop the feeling of a neglected disease."

Patients should talk to their rheumatologists to determine their best course of treatment.

This study was promoted by the APHP clinical research and osteoarthritis group of the French Society, and funding from Inserm pro A and a grant from ABBOTT laboratory.


Story Source:

The above story is based on materials provided by American College of Rheumatology (ACR). Note: Materials may be edited for content and length.


Cite This Page:

American College of Rheumatology (ACR). "Anti-TNF therapy fails to relieve pain caused by hand osteoarthritis, study suggests." ScienceDaily. ScienceDaily, 11 November 2012. <www.sciencedaily.com/releases/2012/11/121111153424.htm>.
American College of Rheumatology (ACR). (2012, November 11). Anti-TNF therapy fails to relieve pain caused by hand osteoarthritis, study suggests. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2012/11/121111153424.htm
American College of Rheumatology (ACR). "Anti-TNF therapy fails to relieve pain caused by hand osteoarthritis, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/11/121111153424.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) — A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) — The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins